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Simple Summary: Plasmodium falciparum (Pf) infection is a risk factor for endemic Burkitt lymphoma
(eBL), the commonest childhood cancer in Africa, but the biomarkers of Pf infection that predict this
risk are unknown. There is some evidence that the genetic complexity of Pf infection may be a risk
factor. In 200 children with versus 140 without eBL in Malawi, this study compared variants of the
malaria parasite, focusing on Pfsera5, a gene that codes for malaria protein that an infected person’s
antibodies target to suppress the parasite. Multiple Pfsera5 variants, which arise when the parasite is
not suppressed, were found in 41.7% of eBL children versus 24.3% of other local children, meaning
that eBL risk was increased 2.4-fold with multiple Pfsera5 variants. No specific type of variant was
related to eBL risk. Research to quantify malaria parasite variants and to clarify the host immune
response needed to control variant infections may yield a test to predict eBL risk.
Abstract: Background: Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in
Africa and is linked to Plasmodium falciparum (Pf ) malaria infection, one of the most common and
deadly childhood infections in Africa; however, the role of Pf genetic diversity is unclear. A potential
role of Pf genetic diversity in eBL has been suggested by a correlation of age-specific patterns of
eBL with the complexity of Pf infection in Ghana, Uganda, and Tanzania, as well as a finding of
significantly higher Pf genetic diversity, based on a sensitive molecular barcode assay, in eBL cases
than matched controls in Malawi. We examined this hypothesis by measuring diversity in Pf-serine
repeat antigen-5 (Pfsera5), an antigenic target of blood-stage immunity to malaria, among 200 eBL
cases and 140 controls, all Pf polymerase chain reaction (PCR)-positive, in Malawi. Methods: We
performed Pfsera5 PCR and sequencing (~3.3 kb over exons II–IV) to determine single or mixed
Pf SERA5 infection status. The patterns of Pfsera5 PCR positivity, mixed infection, sequence variants,
and haplotypes among eBL cases, controls, and combined/pooled were analyzed using frequency
tables. The association of mixed Pfsera5 infection with eBL was evaluated using logistic regression,
controlling for age, sex, and previously measured Pf genetic diversity. Results: Pfsera5 PCR was
positive in 108 eBL cases and 70 controls. Mixed Pf SERA5 infection was detected in 41.7% of eBL
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cases versus 24.3% of controls; the odds ratio (OR) was 2.18, and the 95% confidence interval (CI)
was 1.12–4.26, which remained significant in adjusted results (adjusted odds ratio [aOR] of 2.40,
95% CI of 1.11–5.17). A total of 29 nucleotide variations and 96 haplotypes were identified, but these
were unrelated to eBL. Conclusions: Our results increase the evidence supporting the hypothesis
that infection with mixed Pf infection is increased with eBL and suggest that measuring Pf genetic
diversity may provide new insights into the role of Pf infection in eBL.
Keywords: Plasmodium falciparum; Burkitt lymphoma; Epstein Barr virus; epidemiology; Africa;
complexity of infection
1. Introduction
Endemic Burkitt lymphoma (eBL) is an aggressive B-cell non-Hodgkin lymphoma
(NHL), first described in African children by Denis Burkitt in 1958 [1]. High incidence of eBL
overlaps with holoendemic Plasmodium falciparum (Pf ) infection in Africa [2], and it is one of
the commonest childhood cancers [3] in countries with high malaria endemicity, including
Malawi, Uganda, Tanzania, and Kenya [4]. The eBL incidence is 30-fold higher in these
countries than in non-malaria endemic countries [5]. The correlation of eBL with malaria
in population-based and individual-level studies, the findings of altered anti-Pf antibody
levels in eBL cases compared to healthy children [6–8], and the reduced frequency of genetic
variants that protect against malaria in eBL cases compared to healthy children [9,10]
suggest that malaria infection may be related to eBL risk. Biologically, Pf may increase
eBL risk directly by stimulating the polyclonal expansion of B lymphocytes, triggering
chromosomal instability in B cells [11,12], or indirectly, by impairing immunologic control
of the Epstein–Barr virus (EBV), a known carcinogen for eBL [13].
The biomarkers of Pf related to eBL are unknown. A correlation study of 2602 cases in
Ghana, Uganda, and Tanzania with published biomarkers (parasitemia, parasite density,
and genetic diversity of parasites) of Pf infection in the same countries [14] was the
first to suggest that Pf genetic diversity may be related to eBL, based on a significant
association between age-specific patterns of eBL and Pf genetic diversity. This hypothesis
was evaluated among 303 eBL cases and 274 controls in Malawi by measuring Pf diversity
using a Pf 3D7 molecular barcode assay [15]. The results showed a significantly higher
mean Pf genetic diversity score in the eBL cases than the controls [16]. Although these two
studies represent the only evidence linking Pf genetic diversity with eBL, the results may
be valid because they are based both on population- and individual-level designs, and an
assessment of Pf diversity using a sensitive and specific molecular assay.
In the present study, we investigated whether the presence of mixed infection at the
Pf serine repeat antigen-5 (Pfsera5) locus (on chromosome 2) [17] is associated with eBL
in Malawi. Pfsera5 has been identified as a blood-stage vaccine candidate [18,19], in part
because antibodies targeting Pfsera5, measured using SE36—a recombinant molecule of
Pf SERA5 [20]—were protective against malaria and eBL [7]. The potential as a vaccine
target also prompted interest in the genetic diversity at this locus. Pfsera5 codes for a
120-kDa precursor (Figure 1A), which is critical to Pf blood-stage infection (and egress
from the parasitophorous vacuole) and is an antigenic target of blood-stage immunity to
malaria [21]. The Pf SERA5 precursor is processed by removing the signal peptide and the
protein trimmed into three fragments: the P47, P56, and P18 kDa domains; P56 is further
processed to P50 and P6 fragments [22–25]. Pfsera5 sequence diversity is introduced by
insertions and deletions in the P47 fragment in the protein domain containing the octamer
and serine repeats (where protective epitopes are located) [26], and by point mutations in a
stretch without repeats [27], but the association of Pfsera5 diversity with eBL is unknown.
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Figure 1. Structure, divergence, and polymorphism of the P. falciparum sera5 gene. (A) Schematic structure of SERA5.
Numbers are the amino acid positions of SERA5 in the P. falciparum 3D7 strain. (B) Amino acid sequence of SERA5 from P.
falciparum 3D7. Polymorphic amino acid residues are highlighted in light blue. Positions with synonymous amino acid
changes are highlighted in light green. The signal peptide region is shown in purple. Octamer repeats are shown in red. The
serine repeat region with a 13-mer insertion/deletion region and a dimorphic 17-mer region are shown in pink.
2. Materials and Methods
2.1. Study Patients
The study was conducted in the Infections and Childhood Cancer study in Malawi [28].
Briefly, children aged 0 to 15 years diagnosed with cancers (eBL, leukemia, Hodgkin lym-
phoma, neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma, primitive neuroectodermal
tumor, and Wilms’ tumor) were enrolled at the Queen Elizabeth Hospital in Blantyre,
Malawi between July 2005 and August 2010. All children were reviewed by one inves-
tigator (EM) to verify clinical diagnosis. Confirmation by histology, cytology, or other
laboratory investigations was done when possible. Children with eBL were coded as cases
and those with another diagnosis were coded as controls [16]. Children with HIV infection
and those with Kaposi sarcoma were excluded. The current study included only children
who were Pf -infected based on polymerase chain reaction (PCR) performed on samples
taken at the time of diagnosis, before initiating cancer treatment targeting a 519-base pair
(bp) segment of the PF07-0076 locus [16].
2.2. Ethics Review
Ethical approval was given by the Malawian College of Medicine Research and Ethics
Committee (P.03/04/277R) and the Office of Human Subjects Research at the National Institutes
of Health (Exempt #: 4742). The parents/guardians of the children gave written informed consent.
2.3. Laboratory Methods
2.3.1. Pfsera5 Gene Amplification
The Pf SERA5 amplification was performed on residual genomic DNA extracted from
coded/masked whole blood samples taken at the time of diagnosis before initiating cancer
treatment, using a QIAamp Blood DNA Kit (Qiagen, Inc., Valencia, CA, USA) at Osaka
University [16]. The Pf SERA5 PCR amplification targeted the ~3.3 kb region in exons II–IV
using the specific primers sera5-5F0 and sera5-3R0 (Table S1). The sequence before and
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after exon I (encoding the signal peptide) is AT-rich and contains poly-A residues, which
makes it difficult to successfully sequence; thus, this region was excluded in our analysis.
PCR amplification was carried out in a 25-µL reaction mixture containing 0.4 µM each of
forward and reverse primers, 0.4 mM of deoxyribonucleotides (dNTP), 0.5 units of KOD
FX Neo polymerase (TOYOBO Co., Ltd., Osaka, Japan), 12.5 µL of 2× PCR buffer, and 1 µL
of genomic DNA solution. The PCR conditions were as follows: 95 ◦C for 2 min, 40 cycles
of 95 ◦C for 30 s, 59 ◦C for 30 s, and 68 ◦C for 4 min. A 2-µL aliquot of the PCR product
was used as a template for a second PCR amplification in a 25-µL reaction mixture using
the primers sera5-5F3 and sera5-3R2 (Table S1) under the same thermocycler conditions.
Samples that were not successfully amplified using this primer set were re-tested using
nested PCR primers targeting half the original length of the two fragments (a 5′ half and
a 3′ half). The nested primer set used for the 5′ half fragments were sera5-5F0 and sera5-
R0 for the first PCR, and sera5-5F3 and sera5-R0 for the nested PCR; and for the 3′ half
fragments, sera5-F1 and sera5-3R0 were used for the first PCR, followed by sera5-F2 and
sera5-3R2 (Table S1). The nested PCR conditions were the same as for the full-length PCR,
but the extension time was shortened to 2 min. There were 12 duplicate samples included
for quality control. The results were concordant for PCR and PfSERA5 single or mixed
infection in nine samples at the original testing, and three samples were resolved after
re-testing; two were PCR-negative and one was a single infection.
2.3.2. Pfsera5 Nucleotide Sequencing
The PCR products were purified using a QIAquick PCR Purification kit (QIAGEN,
Hilden, Germany) according to the manufacturer’s instructions. Purified DNA fragments
were eluted in 30 µL of Tris-EDTA buffer (TE). The optical density was measured with a
NanoDrop (Thermo Fisher Scientific, Wilmington, DE, USA) and the DNA concentration
was adjusted to 0.026 µg/µL for the 3.3 kb fragments and 0.013 µg/µL for the 5′-half and
3′-half fragments using TE. At this concentration, 1 µL was suitable for performing one
sequencing reaction. Pfsera5 DNA sequencing was performed directly using The BigDye®
Terminator v3.1 Cycle Sequencing Kit and 3130xI Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA). Sequencing primers were designed to cover target regions in both
directions (Table S1). The nucleotide sequences generated during the current study are
available through public database such as DDBJ and NCBI (Accession numbers: LC606291–
LC606405). The sequence results without overlapping peaks on the electropherograms
were interpreted as being single parasite infections; otherwise, the sample was recorded
as having a mixed parasite infection. The Pf SERA5 sequence variations in single parasite
infections were analyzed to get insights into variation in populations.
2.3.3. Sequence Alignment and Pf Population Genetics Analyses
The Pf SERA5 nucleotide sequence obtained from each sample was aligned to the
PfSERA5 3D7 strain using CLUSTALW implemented in GENETYX® ver. 15 (GENETYX Co.,
Ltd., Tokyo, Japan) and the alignment was manually inspected to ensure alignment accuracy.
Analyses were done for the entire sequence and for specific protein domains: the 2562 bp
nucleotide sequence includes a stretch without repeats (a non-repeat region, or NonR); the
stretch of octamer repeats (OctR) and the stretch with serine repeats (SerR) correspond to
amino acid positions 87–193 and 251–997, respectively [27]. The sequence information from
the NonR was translated into its 854 amino acid (aa) sequences to identify nonsynonymous
(variations that result in changes in an aa sequence) versus synonymous (no change in an
aa sequence). To gain insights into Pfsera5 variations in samples from nearby Tanzania or
countries with a high eBL incidence (e.g., Ghana), we accessed the Pfsera5 sequence from
55 asymptomatic donors in the Rufiji River Delta in Tanzania sampled in 1993, 1998, and
2003 (Accession numbers: AB634928–AB634982) [29], and from 33 children in three villages
in Ghana sampled in 2004 (Accession numbers: AB634983–AB635015) [29].
Haplotype diversity (Hd) and nucleotide diversity (π, the average number of nucleotide
differences per site between two sequences in all possible pairs in the sample population) were
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calculated using DnaSP v5.10.01 [30]. The difference between the numbers of synonymous
substitutions per synonymous site (dS) and of nonsynonymous substitutions per nonsynony-
mous site (dN) was calculated by the Nei and Gojobori method [31], implemented in MEGA
X, with the Jukes and Cantor correction. The statistical significance of the difference between
dN and dS was estimated using the MEGA Z-test [32]. Higher dS may suggest that active,
synonymous amino acid substitutions that are neutral or can boost parasite fitness are more
likely to be retained or accumulated, while non-synonymous amino acid substitutions that
reduce parasite fitness are removed or reduced in frequency. Wright’s fixation index Fst was
calculated to assess the genetic differentiation of Pfsera5 among the parasite circulating in the
study population [33]. The pairwise Fst between parasite populations was calculated using
Arlequin v3.5 [34]. A small Fst indicates that the parasite allele frequencies within the study
populations are similar, whereas a large Fst indicates that the allele frequencies are different,
and the study populations do not share genetic diversity.
2.3.4. Statistical Analyses
Patterns of Pfsera5 PCR positivity, mixed Pfsera5 infection, and Pfsera5 haplotypes
and nucleotide diversity in eBL cases or controls, separately or combined/pooled, were
analyzed for the entire Pfsera5 sequence and by domain (OctR, SerR, and NonR). The results
were categorized into known haplotypes; the many “rare haplotypes” (defined among
Malawi controls as SerR haplotypes observed in <10% or OctR haplotypes observed in
<20% of the samples) were grouped and then compared to the common haplotypes. This
grouping is post hoc, but it is useful for exploring pairwise comparisons of common versus
rare haplotypes in eBL cases and controls, as well as haplotype patterns observed in Ghana
and Tanzania. Differences across sample groups were evaluated using Fisher’s exact test.
Because age is an important predictor of exposure and immunity to malaria, the data were
explored by age (<6 versus ≥6 years of age).
The association of mixed PfSERA5 infection with eBL was assessed by calculating odds
ratios and 95% confidence intervals (OR 95% CI) using logistic regression. Bivariate ORs
(bORs) were obtained by adjusting separately for age, sex, and the Pf genetic diversity score
as confounders [16], before including all these variables into one model for multivariate
adjustment (aOR), but the results were not adjusted for multiple comparisons; thus, two-
sided p-values < 0.05 were considered statistically significant. However, other comparisons
must be interpreted cautiously for hypothesis generation.
3. Results
3.1. Characteristics of Study Subjects
The current study evaluated 341 Pf PCR-positive participants. One participant was
>17 years and excluded from subsequent analyses. The remaining participants included
200 eBL cases and 140 controls (Table 1). Most participants were from Malawi (n = 327), but
13 (10 eBL cases and 3 controls) were from Mozambique, a neighboring country. Because
of the small sample size of the children originating in Mozambique, the sequence data
from those children were analyzed together with those from Malawi, where all children
were enrolled. The three leading diagnoses among the controls were renal tumors (n = 28),
non-eBL lymphoma and leukemia (n = 35, including 9 with leukemia), and soft tissue
tumors (n = 19). The eBL cases were slightly older than the controls, but the difference was
not statistically significant (7.2 years versus 6.9 years, p = 0.44). However, the eBL cases
were more likely to be aged 6–10 years than the controls (50.5% versus 25.7%, heterogeneity
<0.001). The male-to-female proportion of eBL cases and controls was not statistically
different in this set (62.5% versus 58.6% in females, p = 0.50).
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Table 1. Characteristics of Malawi and Mozambique samples used in this study.
Subject Characteristics Sample
Size






0–5yrs 6–10yrs 11–15yrs * Negative Positive Single Mixed Indeterminate †
Case Status
Cases 200 125 (62.5) 8 7.2 (2.8) 69 (34.5) 101 (50.5) 22 (11.0) 92 (46.0) 108 (54.0) 63 (58.3) 45 (41.7) -
Controls 140 82 (58.6) 5 6.9 (4.4) 66 (47.1) 36 (25.7) 33 (23.6) 70 (50.0) 70 (50.0) 52 (74.3) 17 (24.3) 1 (1.4)
Association with eBL











Leukemias 9 3 (33.3) 0 7.6 (4.5) 4 (44.4) 2 (22.2) 3 (33.3) 7 (77.8) 2 (22.2) 1 (50.0) 1 (50.0) -
Lymphomas 26 18 (69.2) 1 10.2 (4.1) 4 (16.0) 8 (32.0) 13 (52.0) 13 (50.0) 13 (50.0) 11 (84.6) 2 (15.4) -
Neuroblastomas 8 5 (62.5) 0 7.0 (3.9) 3 (37.5) 4 (50.0) 1 (12.5) 6 (75.0) 2 (25.0) 2 (100.0) 0 (0.0) -
Retinoblastoma 9 3 (33.3) 0 4.0 (2.8) 8 (88.9) 0 (0.0) 1 (11.1) 5 (55.6) 4 (44.4) 2 (50.0) 2 (50.0) -
Renal tumors 28 21 (75.0) 0 3.6 (2.9) 24 (85.7) 3 (10.7) 1 (3.6) 8 (28.6) 20 (71.4) 15 (75.0) 5 (25.0) -
Hepatic tumors 6 3 (50.0) 0 7.6 (2.7) 2 (33.3) 3 (50.0) 1 (16.7) 2 (33.3) 4 (66.7) 3 (75.0) 1 (25.0) -
Bone tumors 2 1 (50.0) 0 10.3 (5.4) 0 (0.0) 1 (50.0) 1 (50.0) 1 (50.0) 1 (50.0) 1 (100.0) 0 (0.0) -
Soft tissue sarcomas 19 14 (73.7) 1 7.8 (4.2) 8 (44.4) 5 (27.8) 5 (27.8) 11 (57.9) 8 (42.1) 6 (75.0) 2 (25.0) -
Germ cell tumors 8 3 (37.5) 0 6.8 (4.0) 4 (50.0) 2 (25.0) 2 (25.0) 3 (37.5) 5 (62.5) 3 (60.0) 2 (40.0) -
Epithelial tumors 2 0 (0.0) 0 6.7 (7.8) 1 (50.0) 0 (0.0) 1 (50.0) 1 (50.0) 1 (50.0) 1 (100.0) 0 (0.0) -
Other tumors 1 0 (0.0) 0 13.5 (-) 0 (0.0) 0 (0.0) 1 (100.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Non-malignancies 10 6 (60.0) 0 7.3 (4.7) 3 (30.0) 5 (50.0) 2 (20.0) 5 (50.0) 5 (50.0) 4 (80.0) 0 (0.0) 1 (20.0)
Not well specified 12 5 (41.7) 3 6.2 (4.6) 5 (55.6) 3 (33.3) 1 (11.1) 7 (58.3) 5 (41.7) 3 (60.0) 2 (40.0) -
* Two controls between 16 and 16.2 years; † Unclear if positive infection detected was single or mixed; ‡ Odds ratio adjusted for diversity score, DNA copy number, gender, and age.
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Pfsera5 PCR positivity was detected in 108 (54.0%) eBL cases and 70 (50.0%) controls
(Table 1). The PCR product was insufficient in one control sample and cannot be conclu-
sively ascertained if the sample is a single or mixed Pfsera5 infection. Likewise, not all Pf
positive samples were suitable for amplification of the near full-length Pfsera5, due mainly
to the quality of samples available for the study.
3.2. Association of Mixed Pfsera5 Infection with eBL
Pfsera5 sequences revealed mixed infection in 45 (41.7%) eBL cases and 17 (24.3%)
controls. Mixed Pfsera5 infection was associated with eBL risk in crude analysis (cOR of
2.18, 95% CI of 1.12–4.26: Table 1; Table S2) and in bivariate analyses adjusting for gender
(bOR of 2.18, 95% CI of 1.12–4.26), Pf diversity score (bOR of 2.23, 95% CI of 1.10–4.53), Pf
DNA copy number (bOR of 1.95, 95% CI of 0.96–3.95), and age group (<6, 6–10, 11+ years)
(bOR of 2.44, 95% CI of 1.12–4.26). The association of mixed Pfsera5 infection with eBL
remained in models adjusting for all the variables above (aOR of 2.40, 95% CI of 1.11–5.17).
3.3. Pfsera5 Haplotype Diversity in eBL Cases and Controls in Malawi
Analysis of Hd and π were calculated for 115 samples in Malawi and 88 individuals
in Tanzania and Ghana with single Pfsera5 infection. As shown in Figure 1B, the parasites
harbored variants at 29 nucleotide positions in the sequenced 2562 bp NonR region; 17 led
to nonsynonymous amino acid changes (highlighted orange) and 12 led to synonymous
amino acid changes (highlighted green). The numbers of haplotypes are shown in Table 2.
Analysis of the entire Pfsera5 sequence yielded 96 haplotypes (88 haplotypes at the amino
acid sequence level), 34 in the OctR, 42 in the SerR, and 26 in the NonR regions (Table 2,
detailed in Figures S1 and S2). The Hd for the entire Pfsera5 sequence was 0.993 in eBL
cases, 0.996 in the controls, and 0.991 and 0.996 in the samples from Tanzania and Ghana,
respectively (Table 2). When Hd was considered by Pfsera5 regions, it was lowest for the
NonR region and moderately low for the OctR region; Hd was similar for the entire Pfsera5
and the SerR region, which bears the protective epitopes of Pf SERA5 [26]. Hd in the NonR
region was low in Tanzania (0.362) and Ghana (0.472) compared to that in the eBL cases
and controls combined (0.545) (Malawi and Mozambique).
3.4. Patterns of Common Versus Rare Pfsera5 Haplotypes in eBL Cases and Controls
In analyses restricted to those with a single Pfsera5 infection, the frequency of the
common haplotypes in the OctR and SerR regions was similar in children with eBL and
controls. The common haplotypes in the OctR and SerR regions were more frequent in
the combined eBL cases and the controls in Malawi and Mozambique than in Ghana and
Tanzania (Figure 2, Figures S1 and S2, p < 0.05).
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Table 2. Haplotype diversity of the entire sequence, and the octamer repeat (OctR), serine repeat (SerR), and non-repeat (NonR) 2562 base pair (bp) regions of the P. falciparum SERA5 gene.
Country n















115 96 (88) 0.994 ± 0.003 34 (34) 0.809 ± 0.032 42 (39) 0.935 ± 0.011 26 (16) 0.545 ± 0.011
eBL case 63 54 (50) 0.993 ± 0.005 19 (19) 0.786 ± 0.047 28 (27) 0.928 ± 0.019 16 (9) 0.551 ± 0.075
Control 52 47 (45) 0.996 ± 0.002 21 (21) 0.839 ± 0.040 26 (23) 0.945 ± 0.016 14 (9) 0.544 ± 0.083
Tanzania 55 44 (42) 0.991 ± 0.006 21(21) 0.804 ± 0.054 30 (30) 0.968 ± 0.010 11 (9) 0.362 ± 0.084
Ghana 33 31 (29) 0.996 ± 0.009 16 (16) 0.873 ± 0.048 23 (23) 0.968 ± 0.018 8 (7) 0.472 ± 0.106
The numbers of amino acid sequence variations are shown in parenthesis. eBL: endemic Burkitt Lymphoma, Hd: Haplotype diversity, SD: standard deviation
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Figure 2. Comparison of the proportion of rare and common alleles among endemic Burkitt lymphoma (eBL) cases and
controls. (A) Comparison of the proportion of the rare and common alleles in the octamer repeat (OctR) region. Alleles with
a frequency >0.2 are defined as common alleles, while the rest are defined as rare alleles. (B) Comparison of the proportion
of the rare and common alleles in the serine repeat (SerR) region. Alleles with a frequency >0.1 are defined as common
alleles, while the rest are defined as rare alleles. (C,D) p-values of the Fisher’s exact test (C: OctR region; D: SerR region).
p < 0.05 are shown in red.
3.5. Genetic Differentiation between Parasite Populations
Table 3 shows nucleotide diversity (π) in the 2562 bp NonR and Table 4 shows the
location of the 29 polymorphic sites (12 synonymous and 17 non-synonymous). There are
23 new variations, that is, variations not previously reported, while 6 (5 non-synonymous
and 1 synonymous) have previously been reported [21], but the specific variations were
not different between the cases and controls. The eBL cases, controls, and individuals in
Tanzania and Ghana had similar nucleotide diversity (π). However, the current eBL cases
and controls (combined, Malawi and Mozambique) had dS > dN while the opposite pattern
(i.e., dN > dS) was observed in the samples from Tanzania (p < 0.06) and Ghana (p = 0.0034)
(Table 3). Fst analysis suggested genetic differentiation (p < 0.05) in the OctR and SerR,
but not the NonR regions for parasites in the eBL cases and controls (combined) and in
individuals in Ghana (Table 5). However, Fst analysis did not support evidence of genetic
differentiation between parasites in Malawi and Mozambique versus those in Tanzania
and Ghana.
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π ± SD dS ± SE dN ± SE p Value
Malawi and Mozambique 115 29 12 17 0.00029 ± 0.00004 0.00050 ± 0.00012 0.00024 ± 0.00008 dS > dN: 0.0595
eBL case 63 17 8 9 0.00028 ± 0.00005 0.00055 ± 0.00017 0.00021 ± 0.00009 dS > dN: 0.0450
Control 52 16 6 10 0.00031 ± 0.00006 0.00044 ± 0.00017 0.00027 ± 0.00011 dS > dN: 0.1943
Tanzania 55 11 1 10 0.00021 ± 0.00007 0.00007 ± 0.00007 0.00025 ± 0.00008 dN > dS: 0.0549
Ghana 33 10 1 10 0.00032 ± 0.00011 0.00000 ± 0.00000 0.00040 ± 0.00015 dN > dS: 0.0034
π: nucleotide diversity, SD: standard deviation, dS: the numbers of synonymous substitutions per synonymous site, SE: standard error, dN: nonsynonymous substitutions per nonsynonymous site, eBL: endemic
Burkitt Lymphoma.
Table 4. Sequence variation in P. falciparum sera5 in the non-repeat 2562 bp region. Nucleotide and amino acid positions are numbered after the P. falciparum 3D7 sequence. The number of
isolates with variations are shown. Variations shared with previously reported P. falciparum sera5 sequences in PlasmoDB (https://plasmodb.org/plasmo/ accessed on 23 October 2020)
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Common C K G E G C N L I D V K D R E L M L V D S E V T Q R K
Variation S E S A S Y S F L G L N V K G S V V I N R K F A R H E
Malawi and Mozambique, n = 115 1 - - - 1 1 - - 1 1 1 1 - 1 1 1 12 - 1 1 - 2 1 1 1 - -
eBL case, n = 63 1 - - - 1 - - - - 1 1 - - - - 1 6 - - 1 1 1 - -
Control, n = 52 - - - - - 1 - - 1 - - 1 - 1 1 - 6 - 1 1 - 1 1 - - - -
Tanzania, n = 55 - 1 1 - 2 - 1 - 1 - - - 2 - - - 3 - - - 1 - - - - 1 1
Ghana, n = 33 - 1 1 1 1 - - 1 1 - - - - - - - 4 1 - - - - - - - 1 1
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Amino Acid G G L E S D P S S G Y G L
Malawi and Mozambique, n = 115 2 1 - 1 1 1 1 1 1 1 2 2 1
eBL Case, n = 63 2 1 - 1 1 1 - 1 - - 1 1 -
Control, n = 52 - - - - - - 1 - 1 1 1 1 1
Tanzania, n = 55 - - - - - - - - - - 1 - -
Ghana, n = 33 - - 1 - - - - - - - - - -
Cancers 2021, 13, 1692 12 of 17




Malawi and Mozambique Tanzania Ghana
All eBL Case Control All All
(A) Octamer repeat region
Malawi and
Mozambique
Combined - 0.9910 0.9910 0.0721 0.0360
eBL case −0.0094 - 0.4595 0.1171 0.0090
Control −0.0097 −0.0030 - 0.0811 0.0270
Tanzania All subjects 0.0113 0.0085 0.0130 - 0.0811
Ghana All subjects 0.0291 0.0271 0.0286 0.0104 -
(B) Serine repeat region
Malawi and
Mozambique
Combined - 0.9910 0.9910 0.0811 0.0000
eBL case −0.0093 - 0.6216 0.0541 0.0000
Control −0.0096 −0.0027 - 0.3604 0.0451
Tanzania All subjects 0.0069 0.0100 0.0013 - 0.2072
Ghana All subjects 0.0202 0.0204 0.0181 0.0039 -
(C) Non-repeat 2562 bp sequence
Malawi and
Mozambique
Combined - 0.9910 0.9910 0.2973 0.5676
eBL case −0.0099 - 0.9279 0.4234 0.5946
Control −0.0105 −0.0056 - 0.2342 0.8018
Tanzania All subjects 0.0011 −0.0002 0.0023 - 0.5586
Ghana All subjects −0.0033 −0.0037 −0.0067 −0.0044 -
Fst values are shown in the bottom left and p-values are shown in the upper right. p < 0.05 are shown in bold. eBL: endemic Burkitt Lymphoma.
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4. Discussion
We investigated the hypothesis that Pf genetic diversity, based on the detection of
mixed Pfsera5 infection, is associated with eBL in Malawi [16]. Our findings of 2.40-fold
higher odds of mixed Pf SERA5 infection in eBL cases than controls, which remained
statistically significant after the adjustment of confounders, including gender, age group, Pf
DNA copy, and Pf genetic diversity [16], led us to reject the null hypothesis. These results
strengthen the evidence that Pf genetic diversity may be related to eBL, as highlighted in
our earlier ecological study in Uganda, Tanzania, and Ghana [14] and in our case-control
in Malawi using a sensitive molecular assay [16].
There is accumulating evidence that mixed Pf infection may be a molecular surro-
gate of chronic asymptomatic Pf infection in high malaria transmission areas [35]. The
consequences for malaria risk appear similar to earlier studies, that is, the risk for malaria
(infection and symptoms) is high in children below age 5 [36,37] but low in children
above age 5 [38], consistent with the level of acquired immunity against malaria at those
ages [39]. Thus, in older children, mixed infection appears to be a molecular marker of
asymptomatic infection [35], incomplete clearance of parasites [40], clinical and parasite
immunity [41], and, according to our results, eBL risk. A recent finding of a median of
the multiplicity of infection of six haplotypes in infective mosquitoes suggests that mixed
infections may arise from co-transmission of genetically diverse oocysts from a single
mosquito bite [35]. Super-infection, that is, the inoculation of different parasites from
different mosquitoes, is also possible [42] in partially immune people living in malarious,
non-sheltered environments [43].
Chronic, asymptomatic, low-density parasite infection has been reported in eBL cases
and may precede the disease [40]. Asymptomatic infection is due, in part, to antibodies
that target parasite proteins, particularly those that are secreted and embedded in infected
red blood cell (iRBC) membranes, thereby blocking sequestration and promoting splenic
clearance of iRBCs [44–46], and thus suppressing parasite density and clinical symptoms.
However, because asymptomatic infections are sub-clinical, they remain untreated for
prolonged periods; the associated chronic immune response may lead to eBL as a rare
complication in children unsheltered from malaria [8]. While a strong immune response
may explain the reduced frequency of symptomatic malaria and lower parasite densities
in eBL cases than other children in the same region [40], we speculate that Pfsera5 may
contribute to the molecular camouflage that facilitates a tolerance of low-grade infection
and sets the stage for progression to cancer. Pf SERA5 N-terminal domain decorates
the surface of the merozoite where it tightly binds to a host serum protein, vitronectin,
which in turn binds to another host protein that camouflages the parasite from the host
immune system [47], potentially reducing pressure for mutations in the Pfsera5 gene.
However, this immune response is not completely effective, resulting in immune tolerance,
high antibody titers against Pf SERA5, and low-grade parasitemia [20]. There is still a
dearth of understanding in the chronic nature of malaria infection and how it amplifies or
down-regulates the immune response, although the continuous insult by low-grade, often
genetically complex variants (mean of 4) [35] likely increases the risk of genetic instability
in B cells and their progression to eBL [11]. In agreement with this hypothesis, the spleen is
frequently enlarged in children with asymptomatic Pf infection [48], whom we hypothesize
are the population at risk of eBL [40]. Plausibly, a robust B-cell response promotes survival
against malaria [49], on one hand by suppressing Pf positivity in eBL [40,43,50], while
promoting eBL risk in children with asymptomatic infection, on the other hand.
The use of Pfsera5 molecular data expands our knowledge of variants in Pf field
isolates in countries where eBL incidence is high [4]. Consistent with previous reports [27],
we observed that Pfsera5 is highly conserved with limited evidence of genetic differentiation,
consistent with the frequent gene flow in Africa. We also observed that Pfsera5 diversity
was not unique to Malawi and Mozambique or to eBL cases. These results are reassuring
because our comparisons are based on samples obtained using varied, potentially biased
methods. The samples from Ghana and Tanzania are from specific communities living in
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relatively small geographical areas, whereas the Malawi and Mozambique samples are
from a much larger geographical area. Thus, the observations that no specific Pf variants
or haplotypes are associated with eBL and that both eBL cases and controls in Malawi
harbor common haplotypes are consistent with both groups being exposed to similarly
high environmental pressure of Pf infection [35]. However, we note that rare haplotypes
may be harder to detect because they exist at lower submicroscopic levels. Our findings of
a lower frequency of the common haplotypes in Tanzania and Ghana than in Malawi and
Mozambique may be due to geographic confounding, as noted above.
Our research suggests that molecular markers of Pf genetic diversity may complement
the search for biomarkers of Pf infection related to eBL risk. The general finding that
Pf SERA5 does not show antigenic variation [20] suggests that Pfsera5 might be a good tool
to characterize the genetic complexity of parasite populations in eBL cases and controls.
However, this should be balanced against the likelihood that the sample size will shrink
because amplifying about 3.2 Kb of Pfsera5 requires higher quality gDNA than amplifying
the 519 bp that we used to confirm Pf infection in all our samples. This explains why
our sample size shrunk by 50%. Other limitations of our study include the use of cross-
sectional samples from a case-control study, and the testing of one sample from a single
time point, which underestimates parasite diversity [51]. These limitations are balanced by
our hypothesis-driven approach, our focus on diversity at a locus that is an antigenic target
of blood-stage immunity to malaria, and the use of cancer controls, in whom referral bias
and reverse-causality biases are minimized. Our study included only children who were
confirmed to have Pf infection by PCR [16], which increases the validity of our assumption
that all children were exposed to infection.
5. Conclusions
Our study provides new evidence for the association of mixed Pf infection with eBL
risk in Malawi. Further research utilizing molecular markers of Pf infection may lead to
the discovery of biomarkers of eBL, severe malaria, and/or asymptomatic infection.
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